Morgan Stanley initiated coverage on Optimer Pharmaceuticals OPTR with an Underweight rating and a $11 price target.
Morgan Stanley noted, "Optimer's growth driver is Dificid, approved for treatment of C. diff. Dificid is a best in disease therapy, but reimbursement hurdles, sluggish launch trends, and a lack of clear long-term growth drivers limit our sales expectations (2018 WW revenue ~$285mn). We see OPTR's risk reward as less attractive than others in our coverage universe."
Optimer Pharmaceuticals closed at $12.82 on Wednesday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in